Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;330 (11 June), doi:10.1136/bmj.330.7504.0-b
The cardiovascular safety of non-steroidal anti-inflammatory drugs (NSAIDs) needs to be reconsidered. In a nested case-control analysis, Hippisley-Cox and Coupland (p 1366) determined the comparative risk of myocardial infarction in patients taking cyclo-oxygenase-2 (COX 2) inhibitors and NSAIDs. All drugs in the study were associated with an increased risk of myocardial infarction, which was statistically significant for rofecoxib, diclofenac, and ibuprofen; no protective effect was seen for naproxen. The authors warn that this is an observational study and may be subject to residual confounding that cannot be fully corrected for.
|
|
Credit: SHOUT/REX
|
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses